# A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

> **NCT02444793** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Advanced/Metastatic Solid Tumors

## Interventions

- **DRUG:** PF-05082566
- **DRUG:** KW-0761

## Key facts

- **NCT ID:** NCT02444793
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2017-09
- **Final completion:** 2017-10
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** The study was terminated due to marginal efficacy and change in sponsor prioritization. The combination had a manageable safety profile.
- **Last updated:** 2019-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02444793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02444793, "A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02444793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*